BOSTON, May 04, 2017 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq:PRTK), a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon tetracycline chemistry, today reported financial results for the quarter ended March 31, 2017.
“The announcement of positive top-line data in April from our successful Phase 3 registration study in pneumonia was a critically important milestone in the development of omadacycline,” said Michael Bigham, Chairman and Chief Executive Officer, Paratek. “Together, this study and our previously announced successful Phase 3 study in skin infections satisfy the regulatory filing requirements of our special protocol assessments with the FDA. Our plan is to submit for regulatory approval in the U.S. as early as the first quarter of 2018 with an EMA submission later in 2018. In addition, we recently announced a collaboration with Zai Lab to develop, manufacture and commercialize omadacycline for the greater China region. We also recently made thirteen presentations on omadacycline, including two oral sessions, at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID).”